Clinical Trial Update: Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC) [Phase 2]

View source ↗

Summary

This clinical trial update notes recruitment for a Phase 2 study evaluating the combination of pembrolizumab and olaparib in extensive-stage small cell lung can…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extensive-stage Small Cell Lung Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• Lynparza (olaparib)

Snippet

Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Conditions: SCLC,Extensive Stage | Phase 2 | Status: RECRUITING